Prothena Corporation plc (NASDAQ:PRTA) has a beta value of 0.07 and has seen 0.9 million shares traded in the last trading session. The company, currently valued at $755.48M, closed the last trade at $14.04 per share which meant it gained $1.43 on the day or 11.34% during that session. The PRTA stock price is -195.87% off its 52-week high price of $41.54 and 11.4% above the 52-week low of $12.44. If we look at the company’s 10-day average daily trading volume, we find that it stood at 0.48 million shares traded. The 3-month trading volume is 545.09K shares.

The consensus among analysts is that Prothena Corporation plc (PRTA) is Buy stock at the moment, with a recommendation rating of 1.50. 1 analysts rate the stock as a Sell, while 0 rate it as Overweight. 3 out of 15 have rated it as a Hold, with 11 advising it as a Buy. 0 have rated the stock as Underweight. The expected earnings per share for the stock is -1.02.

Prothena Corporation plc (NASDAQ:PRTA) trade information

Sporting 11.34% in the green in last session, the stock has traded in the red over the last five days, with the highest price hit on recent trading when the PRTA stock price touched $14.04 or saw a rise of 5.26%. Year-to-date, Prothena Corporation plc shares have moved -61.36%, while the 5-day performance has seen it change -3.51%. Over the past 30 days, the shares of Prothena Corporation plc (NASDAQ:PRTA) have changed 0.21%. Short interest in the company has seen 8.06 million shares shorted with days to cover at 17.35.

Wall Street analysts have a consensus price target for the stock at $43, which means that the shares’ value could jump 67.35% from current levels. The projected low price target is $24.0 while the price target rests at a high of $62.0. In that case, then, we find that the current price level is -341.6% off the targeted high while a plunge would see the stock gain -70.94% from current levels.

Prothena Corporation plc (PRTA) estimates and forecasts

Figures show that Prothena Corporation plc shares have outperformed across the wider relevant industry. The company’s shares have lost -28.15% over the past 6 months, with this year growth rate of 18.84%, compared to 17.20% for the industry. Revenue growth from the last financial year stood is estimated to be 54.73%.

8 analysts offering their estimates for the company have set an average revenue estimate of 8.35M for the current quarter. Year-ago sales stood 316k and 50k respectively for this quarter and the next, and analysts expect sales will grow by 2,541.38% for the current quarter and 54.73% for the next.

If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was 6.83% over the past 5 years. Earnings growth for 2024 is a modest 20.56% while over the next 5 years, the company’s earnings are expected to increase by 34.07%.

PRTA Dividends

Prothena Corporation plc is expected to release its next earnings report in January this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.

Prothena Corporation plc (NASDAQ:PRTA)’s Major holders

Insiders own 13.46% of the company shares, while shares held by institutions stand at 96.97% with a share float percentage of 112.05%. Investors are also buoyed by the number of investors in a company, with Prothena Corporation plc having a total of 246.0 institutions that hold shares in the company. The top two institutional holders are ECOR1 CAPITAL, LLC with over 11.58 million shares worth more than $239.1 million. As of 2024-06-30, ECOR1 CAPITAL, LLC held 21.5666% of shares outstanding.

The other major institutional holder is FMR LLC, with the holding of over 8.07 million shares as of 2024-06-30. The firm’s total holdings are worth over $166.48 million and represent 15.016% of shares outstanding.

Also the top two Mutual Funds that are holding company’s shares are Vanguard Specialized-Health Care Fund and Fidelity Growth Company Fund . As of Jul 31, 2024 , the former fund manager holds about 5.59% shares in the company for having 3.01 shares of worth $42.23 million while later fund manager owns 2.36 shares of worth $33.07 million as of Oct 31, 2024 , which makes it owner of about 4.38% of company’s outstanding stock.